

Viktor von Wyl

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6585005/publications.pdf>

Version: 2024-02-01

104
papers

4,286
citations

117571

34
h-index

123376

61
g-index

116
all docs

116
docs citations

116
times ranked

5097
citing authors

#	ARTICLE	IF	CITATIONS
1	Real-world disease-modifying therapy usage in persons with relapsing-remitting multiple sclerosis: Cross-sectional data from the Swiss Multiple Sclerosis Registry. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 60, 103706.	0.9	6
2	Individual-Level Evaluation of the Exposure Notification Cascade in the SwissCovid Digital Proximity Tracing App: Observational Study. <i>JMIR Public Health and Surveillance</i> , 2022, 8, e35653.	1.2	7
3	Swiss chiropractic practice-based research network and musculoskeletal pain cohort pilot study: protocol of a nationwide resource to advance musculoskeletal health services research. <i>BMJ Open</i> , 2022, 12, e059380.	0.8	4
4	Disability progression in relapse-free multiple sclerosis patients on fingolimod versus interferon-beta/glatiramer acetate. <i>Multiple Sclerosis Journal</i> , 2021, 27, 439-448.	1.4	8
5	Temporal trends and regional disparities in cancer screening utilization: an observational Swiss claims-based study. <i>BMC Public Health</i> , 2021, 21, 23.	1.2	2
6	Drivers of Acceptance of COVID-19 Proximity Tracing Apps in Switzerland: Panel Survey Analysis. <i>JMIR Public Health and Surveillance</i> , 2021, 7, e25701.	1.2	83
7	Toward a Working Definition of eCohort Studies in Health Research: Narrative Literature Review. <i>JMIR Public Health and Surveillance</i> , 2021, 7, e24588.	1.2	10
8	Impact of single and combined rare diseases on adult inpatient outcomes: a retrospective, cross-sectional study of a large inpatient population. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 105.	1.2	5
9	Physiotherapy use and access-barriers in persons with multiple sclerosis: A cross-sectional analysis. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 48, 102710.	0.9	3
10	Challenges for Nontechnical Implementation of Digital Proximity Tracing During the COVID-19 Pandemic: Media Analysis of the SwissCovid App. <i>JMIR MHealth and UHealth</i> , 2021, 9, e25345.	1.8	14
11	A Data-Driven Simulation of the Exposure Notification Cascade for Digital Contact Tracing of SARS-CoV-2 in Zurich, Switzerland. <i>JAMA Network Open</i> , 2021, 4, e218184.	2.8	25
12	Relationship between Job Demandsâ€Resources and turnover intention in chronic disease â€“ The example of multiple sclerosis. <i>Stress and Health</i> , 2021, 37, 940-948.	1.4	6
13	Are weak or negative clinical recommendations associated with higher geographical variation in utilisation than strong or positive recommendations? Cross-sectional study of 24 healthcare services. <i>BMJ Open</i> , 2021, 11, e044090.	0.8	1
14	Major depressive disorder subtypes and depression symptoms in multiple sclerosis: What is different compared to the general population?. <i>Journal of Psychosomatic Research</i> , 2021, 144, 110402.	1.2	5
15	The Effect of Depression on Health-Related Quality of Life Is Mediated by Fatigue in Persons with Multiple Sclerosis. <i>Brain Sciences</i> , 2021, 11, 751.	1.1	9
16	Onset Symptom Clusters in Multiple Sclerosis: Characteristics, Comorbidities, and Risk Factors. <i>Frontiers in Neurology</i> , 2021, 12, 693440.	1.1	9
17	Surgical procedures in inpatient versus outpatient settings and its potential impact on follow-up costs. <i>Health Policy</i> , 2021, 125, 1351-1358.	1.4	3
18	The SwissCovid Digital Proximity Tracing App after one year: Were expectations fulfilled? <i>Swiss Medical Weekly</i> , 2021, 151, w30031.	0.8	20

#	ARTICLE	IF	CITATIONS
19	Toward a Common Performance and Effectiveness Terminology for Digital Proximity Tracing Applications. <i>Frontiers in Digital Health</i> , 2021, 3, 677929.	1.5	10
20	Adherence and Association of Digital Proximity Tracing App Notifications With Earlier Time to Quarantine: Results From the Zurich SARS-CoV-2 Cohort Study. <i>International Journal of Public Health</i> , 2021, 66, 1603992.	1.0	14
21	Using Venn Diagrams to Evaluate Digital Contact Tracing: Panel Survey Analysis. <i>JMIR Public Health and Surveillance</i> , 2021, 7, e30004.	1.2	7
22	How do patients enter the healthcare system after the first onset of multiple sclerosis symptoms? The influence of setting and physician specialty on speed of diagnosis. <i>Multiple Sclerosis Journal</i> , 2020, 26, 489-500.	1.4	15
23	Factors influencing patient satisfaction with the first diagnostic consultation in multiple sclerosis: a Swiss Multiple Sclerosis Registry (SMSR) study. <i>Journal of Neurology</i> , 2020, 267, 153-161.	1.8	7
24	Degree of regional variation and effects of health insurance-related factors on the utilization of 24 diverse healthcare services - a cross-sectional study. <i>BMC Health Services Research</i> , 2020, 20, 1091.	0.9	8
25	Exploring geographic variation of and influencing factors for utilization of four diabetes management measures in Swiss population using claims data. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001059.	1.2	3
26	Long-term worsening of different body functions in persons with progressive multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2020, 6, 205521732096451.	0.5	1
27	Going beyond the mean: economic benefits of myocardial infarction secondary prevention. <i>BMC Health Services Research</i> , 2020, 20, 1125.	0.9	1
28	Development and validation of the self-reported disability status scale (SRDSS) to estimate EDSS-categories. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 42, 102148.	0.9	21
29	Factors associated with employment and expected work retention among persons with multiple sclerosis: findings of a cross-sectional citizen science study. <i>Journal of Neurology</i> , 2020, 267, 3069-3082.	1.8	12
30	Insights into the protective effects of influenza vaccination: More hospitalizations but lower follow-up mortality during the 2014/15 influenza season in a Swiss cohort. <i>Vaccine</i> , 2020, 38, 5187-5193.	1.7	2
31	60/30: 60% of the Morbidity-Associated Multiple Sclerosis Disease Burden Comes From the 30% of Persons With Higher Impairments. <i>Frontiers in Neurology</i> , 2020, 11, 156.	1.1	10
32	Variation of colorectal, breast and prostate cancer screening activity in Switzerland: Influence of insurance, policy and guidelines. <i>PLoS ONE</i> , 2020, 15, e0231409.	1.1	14
33	A research agenda for digital proximity tracing apps. <i>Swiss Medical Weekly</i> , 2020, 150, w20324.	0.8	49
34	Social mixing and risk exposures for SARS-CoV-2 infections in elderly persons. <i>Swiss Medical Weekly</i> , 2020, 150, w20416.	0.8	3
35	Early evidence of effectiveness of digital contact tracing for SARS-CoV-2 in Switzerland. <i>Swiss Medical Weekly</i> , 2020, 150, w20457.	0.8	114
36	Proximity to death and health care expenditure increase revisited: A 15-year panel analysis of elderly persons. <i>Health Economics Review</i> , 2019, 9, 9.	0.8	15

#	ARTICLE	IF	CITATIONS
37	A Framework for Estimating the Burden of Chronic Diseases: Design and Application in the Context of Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2019, 10, 953.	1.1	17
38	Patterns of care for Multiple Sclerosis in a setting of universal care access: A cross-sectional study. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 28, 17-25.	0.9	14
39	Cost trajectories from the final life year reveal intensity of end-of-life care and can help to guide palliative care interventions. <i>BMJ Supportive and Palliative Care</i> , 2018, 8, 325-334.	0.8	18
40	Recommended outcome measures for inpatient rehabilitation of multiple sclerosis are not appropriate for the patients with substantially impaired mobility. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 22, 108-114.	0.9	8
41	Variability of Very Low Birth Weight Infant Outcome and Practice in Swiss and US Neonatal Units. <i>Pediatrics</i> , 2018, 141, e20173436.	1.0	34
42	Death at no cost? Persons with no health insurance claims in the last year of life in Switzerland. <i>BMC Health Services Research</i> , 2018, 18, 178.	0.9	1
43	Factors associated with time from first-symptoms to diagnosis and treatment initiation of Multiple Sclerosis in Switzerland. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2018, 4, 205521731881456.	0.5	16
44	Variation of preoperative chest radiography utilization in Switzerland and its influencing factors: a multilevel study with claims data. <i>Scientific Reports</i> , 2018, 8, 17475.	1.6	4
45	The Swiss Multiple Sclerosis Registry (SMSR): study protocol of a participatory, nationwide registry to promote epidemiological and patient-centered MS research. <i>BMC Neurology</i> , 2018, 18, 111.	0.8	44
46	The disease burden of Multiple Sclerosis from the individual and population perspective: Which symptoms matter most?. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 25, 112-121.	0.9	104
47	A digitally facilitated citizen-science driven approach accelerates participant recruitment and increases study population diversity. <i>Swiss Medical Weekly</i> , 2018, 148, w14623.	0.8	34
48	Comparison of three different methods for risk adjustment in neonatal medicine. <i>BMC Pediatrics</i> , 2017, 17, 106.	0.7	7
49	Iron metabolism in patients with Gravesâ€™ hyperthyroidism. <i>Clinical Endocrinology</i> , 2017, 87, 609-616.	1.2	11
50	Regional Variation of Cost of Care in the Last 12 Months of Life in Switzerland. <i>Medical Care</i> , 2017, 55, 155-163.	1.1	30
51	Emergence of Acquired HIV-1 Drug Resistance Almost Stopped in Switzerland: A 15-Year Prospective Cohort Analysis. <i>Clinical Infectious Diseases</i> , 2016, 62, 1310-1317.	2.9	52
52	Do insurers respond to risk adjustment? A long-term, nationwide analysis from Switzerland. <i>European Journal of Health Economics</i> , 2016, 17, 171-183.	1.4	8
53	Failure to pay for social health insurance premiums: Acts of protest or desperation?. <i>Preventive Medicine Reports</i> , 2015, 2, 127-133.	0.8	6
54	Limited clinical benefit of minority K103N and Y181C-variant detection in addition to routine genotypic resistance testing in antiretroviral therapy-naïve patients. <i>Aids</i> , 2014, 28, 2231-2239.	1.0	20

#	ARTICLE	IF	CITATIONS
55	Treatment-Naive Individuals Are the Major Source of Transmitted HIV-1 Drug Resistance in Men Who Have Sex With Men in the Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2014, 58, 285-294.	2.9	75
56	Risk adjustment in aging societies. <i>Health Economics Review</i> , 2014, 4, 7.	0.8	3
57	The Individualized Genetic Barrier Predicts Treatment Response in a Large Cohort of HIV-1 Infected Patients. <i>PLoS Computational Biology</i> , 2013, 9, e1003203.	1.5	19
58	Origin of Minority Drug-Resistant HIV-1 Variants in Primary HIV-1 Infection. <i>Journal of Infectious Diseases</i> , 2013, 208, 1102-1112.	1.9	35
59	Adherence as a Predictor of the Development of Class-Specific Resistance Mutations: The Swiss HIV Cohort Study. <i>PLoS ONE</i> , 2013, 8, e77691.	1.1	49
60	Inferring Epidemic Contact Structure from Phylogenetic Trees. <i>PLoS Computational Biology</i> , 2012, 8, e1002413.	1.5	85
61	Incidence of HIV-1 Drug Resistance Among Antiretroviral Treatment-Naive Individuals Starting Modern Therapy Combinations. <i>Clinical Infectious Diseases</i> , 2012, 54, 131-140.	2.9	32
62	Polymorphic Mutations Associated With the Emergence of the Multinucleoside/Tide Resistance Mutations 69 Insertion and Q151M. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 59, 105-112.	0.9	9
63	Minor Protease Inhibitor Mutations at Baseline Do Not Increase the Risk for a Virological Failure in HIV-1 Subtype B Infected Patients. <i>PLoS ONE</i> , 2012, 7, e37983.	1.1	15
64	Cost-Effectiveness of Tenofovir Instead of Zidovudine for Use in First-Line Antiretroviral Therapy in Settings without Virological Monitoring. <i>PLoS ONE</i> , 2012, 7, e42834.	1.1	14
65	Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. <i>Lancet Infectious Diseases</i> , The, 2011, 11, 363-371.	4.6	345
66	Viral Suppression Rates in Salvage Treatment With Raltegravir Improved With the Administration of Genotypic Partially Active or Inactive Nucleoside/Tide Reverse Transcriptase Inhibitors. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 57, 24-31.	0.9	23
67	Effect of Early Antiretroviral Therapy during Primary HIV-1 Infection on Cell-Associated HIV-1 Dna and Plasma HIV-1 Rna. <i>Antiviral Therapy</i> , 2011, 16, 535-545.	0.6	77
68	Analyzing direct and indirect effects of treatment using dynamic path analysis applied to data from the Swiss HIV Cohort Study. <i>Statistics in Medicine</i> , 2011, 30, 2947-2958.	0.8	12
69	Predictors for the Emergence of the 2 Multi-nucleoside/nucleotide Resistance Mutations 69 Insertion and Q151M and their Impact on Clinical Outcome in the Swiss HIV Cohort Study. <i>Journal of Infectious Diseases</i> , 2011, 203, 791-797.	1.9	9
70	The Role of Migration and Domestic Transmission in the Spread of HIV-1 Non-B Subtypes in Switzerland. <i>Journal of Infectious Diseases</i> , 2011, 204, 1095-1103.	1.9	74
71	Assessing Predicted HIV-1 Replicative Capacity in a Clinical Setting. <i>PLoS Pathogens</i> , 2011, 7, e1002321.	2.1	37
72	Improved Virological Outcome in White Patients Infected With HIV-1 Non-B Subtypes Compared to Subtype B. <i>Clinical Infectious Diseases</i> , 2011, 53, 1143-1152.	2.9	53

#	ARTICLE	IF	CITATIONS
73	Ambiguous Nucleotide Calls From Population-based Sequencing of HIV-1 are a Marker for Viral Diversity and the Age of Infection. <i>Clinical Infectious Diseases</i> , 2011, 52, 532-539.	2.9	127
74	Early Antiretroviral Therapy During Primary HIV-1 Infection Results in a Transient Reduction of the Viral Setpoint upon Treatment Interruption. <i>PLoS ONE</i> , 2011, 6, e27463.	1.1	46
75	HIV-1 transmission after cessation of early antiretroviral therapy among men having sex with men. <i>Aids</i> , 2010, 24, 1177-1183.	1.0	62
76	The impact of the Oâ€‘0 cell on measures of amino acid covariation. <i>Aids</i> , 2010, 24, 159-160.	1.0	2
77	Rational design of HIV-1 fluorescent hydrolysis probes considering phylogenetic variation and probe performance. <i>Journal of Virological Methods</i> , 2010, 165, 151-160.	1.0	33
78	A sequential Cox approach for estimating the causal effect of treatment in the presence of timeâ€‘dependent confounding applied to data from the Swiss HIV Cohort Study. <i>Statistics in Medicine</i> , 2010, 29, 2757-2768.	0.8	61
79	Profound Depletion of HIV-1 Transcription in Patients Initiating Antiretroviral Therapy during Acute Infection. <i>PLoS ONE</i> , 2010, 5, e13310.	1.1	84
80	Epidemiological and Biological Evidence for a Compensatory Effect of Connection Domain Mutation N348I on M184V in HIVâ€‘1 Reverse Transcriptase. <i>Journal of Infectious Diseases</i> , 2010, 201, 1054-1062.	1.9	27
81	Efficient Suppression of Minority Drugâ€‘Resistant HIV Type 1 (HIVâ€‘1) Variants Present at Primary HIVâ€‘1 Infection by Ritonavirâ€‘Boosted Protease Inhibitorâ€‘Containing Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2010, 201, 1063-1071.	1.9	51
82	Molecular Epidemiology Reveals Longâ€‘Term Changes in HIV Type 1 Subtype B Transmission in Switzerland. <i>Journal of Infectious Diseases</i> , 2010, 201, 1488-1497.	1.9	172
83	HIVâ€‘1 Reverse Transcriptase Connection Domain Mutations: Dynamics of Emergence and Implications for Success of Combination Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2010, 51, 620-628.	2.9	26
84	Short Communication: B Cells from HIV-Infected Patients with Primary Central Nervous System Lymphoma Display an Activated Phenotype and Have a Blunted TNF-Î± Response to TLR9 Triggering. <i>AIDS Research and Human Retroviruses</i> , 2010, 26, 1063-1074.	0.5	6
85	Phylogenetic Approach Reveals That Virus Genotype Largely Determines HIV Set-Point Viral Load. <i>PLoS Pathogens</i> , 2010, 6, e1001123.	2.1	108
86	Implementation of Raltegravir in Routine Clinical Practice: Selection Criteria for Choosing This Drug, Virologic Response Rates, and Characteristics of Failures. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010, 53, 464-471.	0.9	17
87	The impact of transmission clusters on primary drug resistance in newly diagnosed HIV-1 infection. <i>Aids</i> , 2009, 23, 1415-1423.	1.0	96
88	Longâ€‘Term Trends of HIV Type 1 Drug Resistance Prevalence among Antiretroviral Treatmentâ€‘Experienced Patients in Switzerland. <i>Clinical Infectious Diseases</i> , 2009, 48, 979-987.	2.9	43
89	Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. <i>Lancet Infectious Diseases</i> , The, 2009, 9, 409-417.	4.6	216
90	African descent is associated with slower CD4 cell count decline in treatment-naive patients of the Swiss HIV Cohort Study. <i>Aids</i> , 2009, 23, 1269-1276.	1.0	28

#	ARTICLE	IF	CITATIONS
91	Divergent effects of cell environment on HIV entry inhibitor activity. <i>Aids</i> , 2009, 23, 1319-1327.	1.0	28
92	Biphasic decay kinetics suggest progressive slowing in turnover of latently HIV-1 infected cells during antiretroviral therapy. <i>Retrovirology</i> , 2008, 5, 107.	0.9	44
93	Potent Human Immunodeficiency Virus-Neutralizing and Complement Lysis Activities of Antibodies Are Not Obligarily Linked. <i>Journal of Virology</i> , 2008, 82, 3834-3842.	1.5	24
94	Transmitted Drug Resistant HIV-1 and Association With Virologic and CD4 Cell Count Response to Combination Antiretroviral Therapy in the EuroSIDA Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 48, 324-333.	0.9	46
95	In Vivo Efficacy of Human Immunodeficiency Virus Neutralizing Antibodies: Estimates for Protective Titers. <i>Journal of Virology</i> , 2008, 82, 1591-1599.	1.5	50
96	Factors Associated with the Emergence of K65R in Patients with HIV-1 Infection Treated with Combination Antiretroviral Therapy Containing Tenofovir. <i>Clinical Infectious Diseases</i> , 2008, 46, 1299-1309.	2.9	35
97	Effects of cognitive behavioral stress management on HIV-1 RNA, CD4 cell counts and psychosocial parameters of HIV-infected persons. <i>Aids</i> , 2008, 22, 767-775.	1.0	48
98	Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey. <i>Aids</i> , 2007, 21, 2223-2229.	1.0	117
99	Emergence of HIV-1 Drug Resistance in Previously Untreated Patients Initiating Combination Antiretroviral Treatment_{title};A Comparison of Different Regimen Types_{title};. <i>Archives of Internal Medicine</i> , 2007, 167, 1782.	4.3	116
100	The ability of four genotypic interpretation systems to predict virological response to ritonavir-boosted protease inhibitors. <i>Aids</i> , 2007, 21, 2033-2042.	1.0	15
101	Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study. <i>Aids</i> , 2007, 21, 2201-2207.	1.0	7
102	Equal Amounts of Intracellular and Virion-Enclosed Hepatitis C Virus RNA Are Associated with Peripheral-Blood Mononuclear Cells In Vivo. <i>Journal of Infectious Diseases</i> , 2006, 194, 1713-1723.	1.9	25
103	Complement Lysis Activity in Autologous Plasma Is Associated with Lower Viral Loads during the Acute Phase of HIV-1 Infection. <i>PLoS Medicine</i> , 2006, 3, e441.	3.9	92
104	The Women's Interagency HIV Study: an Observational Cohort Brings Clinical Sciences to the Bench. <i>Vaccine Journal</i> , 2005, 12, 1013-1019.	3.2	474